B20-B24
Conditions
Interventions
Group 1: Patient-data of consenting HIV-infected therapy-naive patients, who fulfill the inclusion criteria of the study, will be documentetd one-time, at the timepoint when the ART is first prescribe
Sponsors
MSD SHARP & DOHME GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Confirmed infection with HIV-1 (positive HIV test according to appropriate standard practice [e.g. PCR test]) 2) Antiretroviral therapeutic-naïve before the baseline visit 3) Decision on antiretroviral therapy was made before inclusion in the study and prescribed at the baseline visit 4) Baseline visit is a current visit or was not more than 2 years before study start 5) Written informed consent given
Exclusion criteria
Exclusion criteria: 1) Existent contraindication/intolerability against the selected antiretroviral therapy or its components 2) Patients who started their ART before market authorization of the used compound(s) in Germany, e.g. participants of clinical trial(s) 3) Investigator considers patient's available information (especially on concomitant diseases and co-medications) as unreliable or incomplete
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Characterization of the Profile of therapy-naive HIV+ patients starting antivretroviral Treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of the Profiles of HIV+ patients starting on different antiretroviral therapies. | — |
Countries
Germany
Contacts
Public ContactChristine Kögl
MUC Research GmbH
Outcome results
None listed